Joshua Seth Silverman

Joshua Seth Silverman

Auto-generated profile, based on publicly available information

Joshua Seth Silverman

Department of Radiation Oncology, NYU Langone Health, New York, NY

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
CRChad G. Rusthoven
Chad G. Rusthoven
MYMasaaki Yamamoto
Masaaki Yamamoto
DBDenise Bernhardt
Denise Bernhardt
DSDerek E. Smith
Derek E. Smith
DGDexiang Gao
Dexiang Gao
TRTyler P. Robin
Tyler P. Robin
Stereotactic radiosurgery (SRS) has become a well-established first-line therapy for limited brain metastases after multiple phase 3 randomized clinical trials of SRS with and without whole-brain radiotherapy (WBRT) collectively demonstrated no overall survival advantage with the addition of WBRT to SRS despite the superior central nervous system (CNS) control observed with WBRT.1-5 The absence of an overall survival advantage to justify the toxic effects of WBRT on cognitive function and quality of life1,4,6 made SRS alone the preferred treatment for limited brain metastases in most settings.7 However, patients with small cell lung cancer were excluded from the landmark randomized clinical trials2-5,8 that established SRS alone as a first-line strategy, making small cell lung cancer an exception where WBRT has remained the standard of care for limited and even solitary brain metastases.9 Historical reservations regarding SRS alone in small cell lung cancer have included concerns for short interval CNS progression that could potentially lead to a decrease in overall survival with WBRT omission, as well as the paucity of data on first-line SRS in this setting.10

1 September 2004 in Genes & Development
Verified
Journal Article
Open access
PDF file
JSJoshua Silverman
Joshua Silverman
HTHiroyuki Takai
Hiroyuki Takai
SBSara B.C. Buonomo
Sara B.C. Buonomo
FEFrank Eisenhaber
Frank Eisenhaber
TLTitia de Lange
Titia de Lange
We report on the function of the human ortholog of Saccharomyces cerevisiae Rif1 (Rap1-interacting factor 1). Yeast Rif1 associates with telomeres and regulates their length. In contrast, human Rif1 did not accumulate at functional telomeres, but localized to dysfunctional telomeres and to telomeric DNA clusters in ALT cells, a pattern of telomere association typical of DNA-damage-response factors. After induction of double-strand breaks (DSBs), Rif1 formed foci that colocalized with other DNA-damage-response factors. This response was strictly dependent on ATM (ataxia telangiectasia mutated) and 53BP1, but not affected by diminished function of ATR (ATM- and Rad3-related kinase), BRCA1, Chk2, Nbs1, and Mre11. Rif1 inhibition resulted in radiosensitivity and a defect in the intra-S-phase checkpoint. The S-phase checkpoint phenotype was independent of Nbs1 status, arguing that Rif1 and Nbs1 act in different pathways to inhibit DNA replication after DNA damage. These data reveal that human Rif1 contributes to the ATM-mediated protection against DNA damage and point to a remarkable difference in the primary function of this protein in yeast and mammals.

7 April 2018 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
LKLeah M. Katz
Leah M. Katz
THThomas Hielscher
Thomas Hielscher
BLBenjamin Liechty
Benjamin Liechty
JSJoshua Silverman
Joshua Silverman
DZDavid Zagzag
David Zagzag
FSFelix Sahm
Felix Sahm

21 September 2010 in Science Signaling
Verified
Journal Article
Closed access
PDF file
IAIgor Astsaturov
Igor Astsaturov
VRVladimir Ratushny
Vladimir Ratushny
ASAnna Sukhanova
Anna Sukhanova
MEMargret B. Einarson
Margret B. Einarson
TBTetyana Bagnyukova
Tetyana Bagnyukova
EGErica Golemis
Erica Golemis
A targeted RNAi screen reveals potential targets for combination approaches to cancer treatment.

1 January 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
AWAmparo Wolf
Amparo Wolf
KNKyla Naylor
Kyla Naylor
MTMoses Tam
Moses Tam
AHAkram Habibi
Akram Habibi
JNJosef Novotny
Josef Novotny
DKDouglas Kondziolka
Douglas Kondziolka

28 September 2014 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
DKDouglas Kondziolka
Douglas Kondziolka
SSSamuel M. Shin
Samuel M. Shin
ABAndrew Brunswick
Andrew Brunswick
IKIrene Kim
Irene Kim
JSJoshua S. Silverman
Joshua S. Silverman
Stereotactic radiosurgery (SRS) was developed decades ago but only began to impact brain tumor care when it was coupled with high-resolution brain imaging techniques such as computed tomography and magnetic resonance imaging. The technique has played a key role in the management of virtually all forms of brain tumor. We reviewed the radiobiological principles of SRS on tissue and how they pertain to different brain tumor disorders. We reviewed the clinical outcomes on the most common indications. This review found that outcomes are well documented for safety and efficacy and show increasing long-term outcomes for benign tumors. Brain metastases SRS is common, and its clinical utility remains in evolution. The role of SRS in brain tumor care is established. Together with surgical resection, conventional radiotherapy, and medical therapies, patients have an expanding list of options for their care. Clinicians should be familiar with radiosurgical principles and expected outcomes that may pertain to different brain tumor scenarios.